During the event, the Company will provide an update and review of its strategy and pipeline.

The presentations will focus on the unmet medical need, development plans, pre-launch activities and commercialization plans for the investigational drug tiratricol (Emcitate®), being developed as a possible treatment for MCT8 deficiency, as well as additional activities to create and enhance long-term shareholder value.

 

Presentations will be made by members of Egetis’ management team and invited key opinion leaders.